Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Caris Life Sciences announced that researchers from Caris and its Precision Oncology Alliance will present seven studies at the IASLC 2026 World Conference on Lung Cancer, held September 12-15, 2026, in Seoul, South Korea. The lineup includes two mini oral presentations on molecular and immune biomarkers in non-small cell lung cancer, a Poster Tour presentation on transcriptomic subtypes in mesothelioma, and four posters leveraging the Caris clinico-genomic database.
Key figures
- Conference dates
- September 12-15, 2026
- Studies presented
- 7
- Mini oral presentations
- 2
- Itgb6 analysis nsclc samples
- 34022
- Germline alteration rate sclc
- 13.4%
- Germline alteration rate nsclc
- 12.2%
- Ret positive registry patients
- 588
- Nsclc samples prmt5 mtap analysis
- 39124
- Nsclc samples biomarker prevalence analysis
- 43261
- Mesothelioma samples transcriptomic analysis
- 386
- Orr large cell neuroendocrine selective ret inhibitors
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.